Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
64 hedge funds and large institutions have $32.6M invested in Asterias Biotherapeutics Inc. Series A in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
7% more capital invested
Capital invested by funds: $30.5M → $32.6M (+$2.13M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 66 → 64 (-2)
29% less call options, than puts
Call options by funds: $313K | Put options by funds: $439K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$376K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$297K |
| 3 |
State Street
Boston,
Massachusetts
|
+$210K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$192K |
| 5 |
AWS
AJ Wealth Strategies
New York
|
+$97.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$379K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$276K |
| 3 |
Millennium Management
New York
|
-$79K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$75K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
51
Meeder Asset Management
Dublin,
Ohio
| $1K | -$2.02K | -612 | -65% |
|
52
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | -$53 | -16 | -9% |
|
|
53
Millennium Management
New York
| – | -$79K | -23,222 | Closed |
|
|
54
Russell Investments Group
London,
United Kingdom
| – | -$75K | -22,144 | Closed |
|
|
WS
55
Wedbush Securities
Los Angeles,
California
| – | -$64K | -18,698 | Closed |
|
|
TC
56
TFS Capital
West Chester,
Pennsylvania
| – | -$56K | -16,381 | Closed |
|
57
Goldman Sachs
New York
| – | -$36K | -10,581 | Closed |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | -$11K | -3,358 | Closed |
|
|
CG
59
Cutler Group
San Francisco,
California
| – | -$10K | -2,984 | Closed |
|
60
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2.57K | -779 | -94% |
|
61
Barclays
London,
United Kingdom
| – | -$382 | -116 | -62% |
|
|
WAM
62
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| – | +$409 | +124 | New |
|
AST Hedge Fund Activity: Q2 2017 in Review
64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q2 2017, worth a combined $32.6M — up 7% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AST and 10 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 18 added.
The largest buyer was BlackRock, adding an estimated $376K. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $379K.
- 64 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q2 2017, down from 66 in Q1 2017.
- Funds reported $32.6M of Asterias Biotherapeutics Inc. Series A stock for Q2 2017, up 7% quarter-over-quarter.
- 10 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q2 2017 and 11 closed out, a net change of -1 holder.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q2 2017 was BlackRock, an estimated $376K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q2 2017 was Thrivent Financial for Lutherans, an estimated $379K sold.
Based on aggregated 13F filings for Q2 2017.